New Zealand guidelines for biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

New Zealand guidelines for biosimilars

Home/Guidelines | Posted 28/02/2014 0 Post your comment

Last update: 28 February 2014

The regulatory body for approval of medicines in New Zealand is the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). The agency is responsible for the regulation of medicines and medical devices in New Zealand, ensuring that medicines and medical devices are acceptably safe.

Medsafe defines a biosimilar as a new biological product that is similar to another biological medicine that has been granted consent to be marketed in New Zealand (the biological reference).

Medsafe has stated that approval of a biosimilar medicine is based on non-clinical studies (pharmacokinetic and pharmacodynamic studies) as well as comparative human clinical studies. Data provided to support the application should show no important difference between the biosimilar and the reference product in terms of efficacy and safety.

However, consensus regarding the interchangeability of a biosimilar medicine and its reference product has yet to be reached. The prescribing physician should therefore take this into account when considering interchanging the medicines.

Medsafe does not cite any specific New Zealand guidelines for biosimilars, but refers biosimilars manufacturers to both the US Food and Drug Administration draft guidelines and the European Medicines Agency guidelines for more information.

Related articles

US guidelines for biosimilars

EU guidelines for biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Medsafe